Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03577665 |
TitleCurative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer | Phase
Not Applicable
|
Date Added 2018-07-05 |
Location
Korea, Republic of
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03860272 |
TitleFc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer | Phase
Phase 1
|
Date Added 2019-03-01 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States United Kingdom |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Balstilimab, Botensilimab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05973487 |
TitleA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2023-08-03 |
Location
Arizona, United States
California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05976906 |
TitleUniversal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2023-08-04 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05783089 |
TitleMSLN-targeted CAR-T Cells in Solid Tumors. | Phase
Phase 1
|
Date Added 2023-03-24 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05785325 |
TitleRC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-03-27 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
RC48-ADC plus Bevacizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05798533 |
TitleNeo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | Phase
Phase 1
|
Date Added 2023-04-04 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Cyclophosphamide, Fludarabine, Interleukin-2 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05799443 |
TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-04-05 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
cetuximab, Irinotecan Hydrochloride, Tislelizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT00001823 |
TitleEvaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols | Phase |
Date Added 1999-11-04 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05382741 |
TitleAdjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial | Phase
Phase 2
|
Date Added 2022-05-19 |
Location
Italy
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga |
Tags
MSS/ MMRp
|
